🇺🇸 FDA
Patent

US 7388071

Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

granted A61KA61K2239/49A61K2239/50

Quick answer

US patent 7388071 (Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response) held by The Regents of the University of California expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 17 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2239/49, A61K2239/50, A61K2239/55, A61K2239/57